Unbalanced risk-benefit analysis of ADHD drugs - Authors' reply
- PMID: 30401441
- DOI: 10.1016/S2215-0366(18)30396-1
Unbalanced risk-benefit analysis of ADHD drugs - Authors' reply
Comment on
-
Unbalanced risk-benefit analysis of ADHD drugs.Lancet Psychiatry. 2018 Nov;5(11):870-871. doi: 10.1016/S2215-0366(18)30346-8. Epub 2018 Oct 26. Lancet Psychiatry. 2018. PMID: 30401439 No abstract available.
-
Unbalanced risk-benefit analysis of ADHD drugs.Lancet Psychiatry. 2018 Nov;5(11):870. doi: 10.1016/S2215-0366(18)30334-1. Epub 2018 Oct 26. Lancet Psychiatry. 2018. PMID: 30401440 No abstract available.
-
Unbalanced risk-benefit analysis of ADHD drugs.Lancet Psychiatry. 2018 Nov;5(11):871. doi: 10.1016/S2215-0366(18)30349-3. Epub 2018 Oct 26. Lancet Psychiatry. 2018. PMID: 30401442 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical